The role of Traditional Chinese medicine in anti-HBV: background, progress, and challenges
Abstract Chronic hepatitis B (CHB) remains a major world's most serious public health issues. Despite the remarkable effect of nucleos(t)ide analogues (NAs) in inhibiting hepatitis B virus (HBV) deoxyribonucleic acid (DNA) as the first-line drug, there are several limitations still, such as poo...
Main Authors: | Feilin Ge, Yan Yang, Zhaofang Bai, Lanlan Si, Xuemei Wang, Jia Yu, Xiaohe Xiao, Yan Liu, Zhigang Ren |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-12-01
|
Series: | Chinese Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13020-023-00861-2 |
Similar Items
-
Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine
by: Piero Colombatto, et al.
Published: (2022-03-01) -
Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy
by: Meng-Ju Lin, et al.
Published: (2023-07-01) -
TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2023-03-01) -
The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
by: Samuel Hall, et al.
Published: (2020-08-01) -
Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?
by: Nae-Yun Heo
Published: (2017-06-01)